it doesnt require a learning curve from the patient
Corrected Sodium Calculator Estimate sodium corrected for hyperglycemia using common 1.6 and 2.4 correction factors
doi: 10.1371/journal.pone.0204317 42 EverardA.BelzerC.GeurtsL.OuwerkerkJ
Wed Love to Hear From You Travelling with a GLP-1 and want help choosing the right cooler for your trip
You join the Body membership for $45 the first month and $145 thereafter, unlock monthly video or chat check-ins, side-effect guidance, and health coaching
What We Know: Animal studies : Clear increased risk of medullary thyroid cancer in mice and rats Human studies : No definitive increased risk documented Real-world data : Thyroid cancer incidence in semaglutide users remains under 1% Clinical Implications: Avoid semaglutide in patients with: Personal history of medullary thyroid cancer Family history of medullary thyroid cancer Multiple endocrine neoplasia syndrome type 2 (MEN2) Practical Clinical Considerations Patient Selection for Cancer Risk Reduction Consider discussing GLP-1 agonists with patients who have: High obesity-related cancer risk (strong family history, previous cancer) Multiple metabolic risk factors (diabetes, metabolic syndrome) Completed cancer treatment seeking recurrence prevention Counseling Points Emphasize to patients: Cancer risk reduction is a potential benefit , not a guaranteed outcome Weight loss and lifestyle changes remain fundamental to cancer prevention These medications are adjuncts to , not replacements for, proven cancer prevention strategies Long-term safety data is still evolving Monitoring Recommendations For patients on semaglutide: Baseline thyroid examination and family history review Monitor for thyroid symptoms : neck mass, hoarseness, difficulty swallowing Regular follow-up for medication tolerance and efficacy Continue standard cancer screening protocols The Bigger Picture While the cancer prevention data is encouraging, its important to maintain perspective
